

# Just-in-Time Basic Clinical Guidance for Pediatric Respiratory Illness

# Version 1

Background: This document addresses a unique educational need for physicians caring for pediatric patients in receiving center emergency departments. There are multiple facilities with limited pediatric capabilities that care for children as they await transfer or the opening of more high-level pediatric beds. Our intent is to provide basic clinical guidance for respiratory care for children to help in these circumstances. It is expected that this is most valuable as a "just in time" reference for providers with limited pediatric experience. It is not intended in scope to be a pediatric intensive care manual for respiratory illness, but rather the management of patients as they await transfer to a higher level or improvement in their clinical condition.

## Critical disclosures:

\*This document presents an evidence-based approach that is appropriate for most patients. It should be adapted to meet the needs of individual patients and situations and should not replace established protocols or clinical judgment.

\*Ideal care for some of these children may be to transfer to a higher level of care and this guidance should not be used as a substitute for that when transfer is possible and clinically appropriate.

Clinical guidelines:

- 1) Assessment and monitoring:
  - a) Physical Exam
  - b) Vital Signs (important to note age appropriate normal for each child)
  - c) Signs of respiratory distress
    - i) Increased work of breathing
      - (1) retractions (subcostal, intercostal, supraclavicular, tracheal tugging)
      - (2) nasal flaring
      - (3) head bobbing
    - ii) Mental Status Changes
      - (1) early: Irritable, agitated or inconsolable
      - (2) Late: lethargic
    - iii) Rapid Respiratory Rate
    - iv) Sats less than 90%
    - v) Low blood Pressure
    - vi) Blue discoloration
  - d) Auscultation
    - i) Air entry
    - ii) Focality of abnormal lung sounds
    - iii) Presence of wheezes
      - (1) OpenPediatrics: Playlist of open-access educational videos on recognizing and managing pediatric respiratory distress.



# 2) History

- a) Consider factors that may place the child at higher risk:
- b) Patient's medical co-morbidities
  - i) Born less than 34 weeks and now less than 6 months old
  - ii) Chronic Lung disease
  - iii) Anatomic airway defect
  - iv) Prior history of intubation for respiratory illness
  - v) Cardiac disease requiring baseline medical therapies
  - vi) Neuromuscular disease
  - vii) Immunodeficiencies

# 3) Evaluation

- a) Radiology consider if there is focality on lung exam or 1st time wheezing illness.
  - i) Plain chest film note: chest films are generally not required for patients with acute bronchiolitis or known asthma
    - (1) Note presence of pleural effusions. Small effusions (less than 0.25% of the lung space) may be well tolerated without chest tubes. Unilateral process resulting in mediastinal shift needs decompression with a chest tube.
  - ii) CT scan
    - (1) Generally NOT performed; but may be performed in selective cases where complications are present or unclear diagnosis
- b) Labs
  - i) CBC and Complete metabolic Panel
  - ii) Blood gas
    - (1) Important to follow Oxygenation, acidosis, and CO2 levels. Note, rising CO2 levels may be more apparent than low oxygen in many cases. Markedly elevated CO2 levels may be a sign of impending respiratory failure and the need for a ventilator.
  - iii) CRP and Sed Rate
  - iv) RVP (respiratory viral panel swab)
- 4) Management of Acute Respiratory Failure
  - a) Oxygenation/Ventilatory Support evaluate whether you need to support oxygenation vs ventilation. Oxygenation is needed for hypoxia and supported through the addition of supplemental oxygen. Ventilation is needed for work of breathing/hypercarbia and supported through high flow/non-invasive positive pressure support.
    - i) Low flow nasal cannula
      - (1) Supplemental oxygen should be provided if saturations persistently fall below 90%. The goal is to provide oxygen to maintain saturations at or above 90%.
      - (2) Oxygen is supplied via nasal cannula, using the lowest flow possible.
      - (3) Oxygen saturation drops to 88% are acceptable during sleep
      - (4) <20 second drops in saturations to the 80s in the sleeping child do not require supplemental oxygen; these may occur in healthy infants (Hunt 1999)
      - (5) Deeper self-resolving desaturations may not be clinically meaningful in mild-to-moderate bronchiolitis patients, who should therefore be taken off continuous pulse oximetry once off supplemental oxygen (Principi 2016)



- ii) High flow nasal cannula
  - (1) HFNC Clinical Pathway options and resources https://files.asprtracie.hhs.gov/documents/aspr-tracie-ta---pediatrics-and-high-flow-nasal-cannulas.pdf
- iii) CPAP
- iv) Invasive airway
  - (1) LMA / Intubation
- 5) Medications that could be used in pediatric respiratory illness


Note: Refer to your institution guidelines for conservation plans for medications on shortage or anticipated shortage.

- a) Tamiflu
  - i) Indications: Clinical benefit is greatest if initiated within 48 hours. In patients with severe, complicated, or progressive illness, hospitalized patients, or those at increased risk for complications, initiate treatment as soon as possible even if >48 hours have elapsed since illness onset and do not delay for laboratory confirmation. For symptomatic outpatients with mild illness not at increased risk for complications, treatment can be considered if it can be initiated ≤48 hours following illness onset. Usual duration of therapy is 5 days; a longer duration can be considered in severely ill or immunocompromised patients (CDC 2021a).
  - ii) Dosing:
    - (1) Infants
      - (a) ≤8 months: Oral: 3 mg/kg/dose twice daily (AAP 2021; CDC 2021a; IDSA [Uyeki 2019]).
      - (b) ≥9 months: Oral: 3.5 mg/kg/dose twice daily (AAP 2021; IDSA [Uyeki 2019]); some experts still recommend manufacturer labeled dosing of 3 mg/kg/dose twice daily (CDC 2021a; IDSA [Uyeki 2019]).
    - (2) Children and Adolescents:
      - (a)  $\leq$ 15 kg: Oral: 30 mg twice daily.
      - (b) >15 to 23 kg: Oral: 45 mg twice daily.
      - (c) >23 to 40 kg: Oral: 60 mg twice daily.
      - (d) >40 kg: Oral: 75 mg twice daily.
- b) Nebulized epinephrine
  - i) Consider inhaled epinephrine for stridor at rest
    - (1) Racemic <4 years 0.05mL/kg up to 0.5mL mixed with 3 mL NS given via nebulizer over 15 min prn q 1-2 hr; > or = 4 years 0.5 mL/dose inhaled
    - (2) Alternative to racemic epinephrine : Epinephrine (1:1000 or 1 mg/mL) < 4 years 2.5mL nebulized and 4 or greater 5mL nebulized
  - ii) Albuterol used as trial for wheezing or for known asthma
    - (1) Indications: asthma or bronchospasm
    - (2) Dosing:
      - (a) Nebulized: 2.5 mg 10 mg every 20 minutes to 4 hours as needed
      - (b) MDI: 2-8 inhalations, utilizing a spacer, every 20 minutes to 4 hours as needed
      - (c) Continuous administration
        - (i) <20 kg 10 mg/hr
        - (ii) >20 kg 20 mg/hr
        - (iii) mL/hr will depend on the method of administration.




- 1. Examples: Mistifinity= 30mL/hr, Aerogen= 12mL/hr. Consult respiratory therapist to help determine the method and nebulization flow rate (mL/hr) of the albuterol in your positive pressure equipment
- 2. If using a standard nebulizer, the mL/hr rate will be determined by flow rate of medical air/oxygen and the actual nebulizer being used. Consult respiratory therapist to assist with the estimated nebulization flow rate (mL/hr)
- 3. Mistifinity calculations example:
  - a. 1.25 mg/3 mL x#40 nebs= 50mg/120mL
    - i. infused/nebulized at 30mL/hr=~10 mg/hr
  - b. 2.5 mg/3 mL x#40 nebs= 100 mg/120mL
    - i. infused/nebulized at 30mL/hr=~20 mg/hr
- c) Steroids
  - i) Indications: asthma, airway edema
    - (1) Dexamethasone: 0.6mg/kg (Max 16mg) po once, may repeat in 24hr
    - (2) Prednisolone:
      - (a) Infants and Children <12 years: Oral: 1 to 2 mg/kg/day in 2 divided doses; continue until peak expiratory flow is 70% of predicted or personal best; maximum daily dose: 60 mg/day.
      - (b) Children ≥12 years and Adolescents: Oral: 40 to 80 mg in divided doses 1 to 2 times daily until peak expiratory flow is 70% of predicted or personal best.
- d) Dexmedetomidine 4 mcg/mL
  - i) Indication: sedation to tolerate face mask or positive pressure
  - ii) Dosing
    - (1) Starting rate: 0.3 mcg/kg/hr
    - (2) Minimum rate: 0 mcg/kg/hr
    - (3) Max rate: 1 mcg/kg/hr
    - (4) Titration: 0.1 mcg/kg/hr every 10 min to maintain SBS of -1 to 0 or NPASS of -3 to -4.
    - (5) Additional: For bradycardia notify LIP for faster titration and order modification
- e) IV fluids use if patient has signs or symptoms of dehydration.
  - i) Recommended maintenance IV fluids using Isotonic solutions (NS or LR)
    - (1) Maintenance fluid calculation: "4-2-1 rule."
      - (a) 4 mL/kg/hr for the first 10 kg of weight, 2 mL/kg/hr for the next 10 kg, and 1 mL/kg/hr for each kilogram thereafter
    - (2) Preferred maintenance fluid should contain dextrose in a NPO child.
      - (a) D5 + 0.9% or 0.45% NS +/- KCl 20 mEq/L (KCl depends on age and labs)
      - (b) D5LR
    - (3) Bolus Fluids- isotonic fluids (NS or LR)
- f) Antibiotics
  - i) Not recommended unless there is clinical suspicion for a bacterial infection.
  - ii) Community acquired Pneumonia antibiotics
    - (1) Children's Hospital of Philadelphia, Clinical Pathway for CAP
    - (2) https://www.chop.edu/clinical-pathway/pneumonia-community-acquired-clinical-pathway
  - iii) See Appendix E for recommended antibiotics from UpToDate.


















#### Additional Care Considerations

#### **Observation and Home Oxygen Therapy**

#### Infants with bronchiolitis with hypoxia may be considered for home oxygen therapy by nasal cannula.

An observation period of a minimum of 6 hours to determine if a child on a small amount of oxygen (s0.5 L/min NC O2 <12 mo old,</li>
 s0.75 L/min NC O2 ≥12 mo old) can be discharged home with oxygen supplied by a home-health company and follow-up with a primary care provider within 48 hours. This period of observation can be safely completed in the emergency department, in a dedicated observation unit, or in a hospital unit.

#### **Pulse Oximetry**

Don't use continuous pulse oximetry routinely in children with acute respiratory illness unless they are on supplemental oxygen.
 Spot checks are indicated to help determine if supplemental oxygen might be beneficial. If on supplemental oxygen therapy, then continuous monitoring should be implemented.

The utility of continuous pulse oximetry in pediatric patients with acute respiratory illness is not well established. Use of continuous pulse
oximetry has been previously associated with increased admission rates and increased length of stay. The clinical benefit of continuous pulse oximetry
without a specific indication (supplemental oxygen is required) is not validated or well documented.

Bronchodilators

#### Don't routinely use bronchodilators in children with bronchiolitis.

Published guidelines do not advocate the routine use of bronchodilators in patients with bronchiolitis. Comprehensive reviews of the literature
have demonstrated that the use of bronchodilators in children admitted to the hospital with bronchiolitis has no effect on any important
outcomes. There is limited demonstration of clear impact of bronchodilator therapy upon the course of disease. Additionally, providers should
consider the potential impact of adverse events upon the patient. However, bronchodilators remain an important part of therapy for reactive airway
disease (asthma exacerbations).

#### Corticosteroids

· Don't use systemic corticosteroids in children under 2 years of age with an uncomplicated lower respiratory tract infection-

- Steroid therapy or Nebulized Racemic Epinepherine might be indicated for upper airway disease (croup).
- Published guidelines recommend that corticosteroid medications not be used routinely in the management of bronchiolitis. Furthermore,
- additional studies in patients with other viral lower respiratory tract infections have failed to demonstrate any benefits.

#### **Chest Radiography**

Don't order chest radiographs routinely in children with uncomplicated asthma or bronchiolitis.

National guidelines articulate a reliance on physical examination and patient history for diagnosis of asthma and bronchiolitis in the pediatric
population. Multiple studies have established limited clinical utility of chest radiographs for patients with asthma or bronchiolitis. Omission of the
use of chest radiography will reduce costs, but not compromise diagnostic accuracy and care. Chest radiography might be indicated for children
requiring ICU care, with bacterial pneumonia, with cardiac disease, or in response to decreased air movement (evaluation for pneumothorax or pleural
effusion).

#### Antibiotics

Don't administer or prescribe antibiotics for children with uncomplicated bronchiolitis.

Treatment with antibiotics has no effect on length of illness, length on supplemental oxygen, or length of hospitalization. In the emergency
department, chest radiography is not helpful to determine if a child has pneumonia and would benefit from antibiotics. It is recommended to rely
upon cultures, Viral panels, WBC levels, fevers, and clinical history all combined to help determine concern for bacterial vs viral etiology.

\*Sources 1-11 in the reference section




Appendix A: Heated High Flow Oxygen Therapy

# Emergency Department Heated Humidified High Flow Nasal Cannula Respiratory Care Pathway

Consider initiation of HHHFNC in the EMERGENCY DEPARTMENT for any of the following situations <u>despite</u> diligent nasopharyngeal (infant) or oropharyngeal (older child) suctioning and repositioning to optimize respiratory status:

• Substantially increased work of breathing (work of breathing score ≥5 for patients less than 5 years old)

- SpO2 consistently <92% despite administration of supplemental oxygen at 4 L/min via conventional nasal cannula (FiO2 1.0)
- Acute hypercarbia with a capillary blood gas pH ≤7.30





# Appendix B: Respiratory distress / asthma severity score

	0	1	2	3
Oxygenation	> 98% on RA	95% - 97% in RA	90% - 94% on RA	< 90% on RA
Auscultation	No wheezing Normal breath sounds	End expiratory wheezes	Inspiratory and expiratory wheezes	Wheezing audible w/o stethoscope or silent chest
Retractions	No retractions	Intercostal retractions and/or diaphragmatic (belly) breathing	<ul> <li>2 of the following:</li> <li>Intercostal</li> <li>Suprasternal</li> <li>Diaphragmatic (belly) breathing</li> <li>Nasal flaring (infant)</li> </ul>	B of the following: Subcostal Intercostal Substernal Supraclavicular Nasal flaring or Head bobbing (infant)
Dyspnea	Absent dyspnea; speaks in complete sentences; alert; playful	Normal activity and speech. Some dyspnea, irritable, coughing after play	Decreased activity 5-8 word sentences. Moderate dyspnea; not sleeping or eating; coughing after play	Not speaking. Severe dyspnea; grunting; lethargic, stops playing
Resp Rate			A second se	
Infant (birth – yr)	< 60	60-80	81-99	≥ 100
Toddler (>1-3 yrs)	< 40	40-60	61-79	≥80
Preschool (>3-6 yrs)	< 30	30-40	41-59	≥ 60
School Age (>6 -12 yrs)	< 20	20-26	27-30	≥31
Adolescent (>12-18 yrs)	<18	18-23	24 - 27	≥28
Severity Scores	0	1-5 MILD	6-10 MODERATE	11-15 SEVERE

# Modified Pediatric Asthma Severity Score (MPASS)



Appendix C: WRAPEM JIT Guidebook - Respiratory Section

# **Respiratory Management**

*Effective bag-mask ventilation skills are your best friend in pediatrics and may prevent unnecessary field intubations.* 

# Remember:

Infants and young children have big occiputs, causing the neck to have a tendency towards flexion. Extension of the neck should be the first step in correcting an airway issue for these patients.

Try to avoid overventilation. Overventilation contributes to gastric distention, emesis, and potential aspiration which can further worsen a tenuous respiratory status.

Endotracheal tube size can be calculated by using the equation, "Age (in years)/4 + 4".

# Remember: Big heads, big tongues, big tissues, and big forces can cause airway obstruction



You are already experienced in airway management for the adult population. Most of those skills can be applied to pediatric airway management with adjustments.

Therefore, this section will focus on the key differences for airway management in the pediatric population.

# Anatomy:


## Infants and young children:

- 1. Anatomic differences increase the opportunity for airway obstruction in this age group. See image below.
  - a. In the supine position their large occiputs cause flexion of the neck
  - b. Increased amounts of soft tissue, as well as a flexible trachea can add pressure to the tracheal rings
  - c. External forces, like cricoid pressure can cause tracheal collapse
  - d. Large tongues relative to the size of the oral cavity.



- 2. Anatomic differences predispose young infants to respiratory failure.
  - a. Young infants preferentially breathe through their noses and during oral breathing, must use soft palate muscles to maintain an open oral airway
  - b. Higher metabolic rates cause infants to use more oxygen per minute per kg of body weight than adults
  - c. Compliant chest walls and other unique lung physiology means that this population has to increase their respiratory rate to increase their ventilation, placing them at risk for respiratory muscle fatigue

Narrow nostrils, newborn obligate nose breather



#### From:

https://www.anesthesiologynews.com/Review-Articles/Article/08-19/10-Common-Pediatric-Airway-Problems-And-Their-Solutions/55657?sub=B9BFD2B22AAB91 C738BEFA44BD6987A27AB424466CD7E09740FF4A4786780, accessed 08/25/2021

By age 8, the pediatric airway is very similar to the adult airway.



# **Airway Management:**

# Non Invasive Interventions:

Reposition: Continue to use jaw thrust and/or chin lift techniques to maintain the neutral position of the airway, which will facilitate improved oxygenation and ventilation.

Use suction liberally but safely.

If croup or epiglottitis is suspected (exhibit Inspiratory stridor, do not suction. Use comforting measures to prevent crying and agitation that could result in further obstruction.

# **Oxygen Delivery:**

a. Continue use of nasal cannulas, face masks, non rebreather masks

**Tip:** Apply adhesive (e.g. tape/band-aids) to the oxygen piping that overlays the patient's cheeks in order keep the cannula in place and prevent removal.

# Oral (OPA) and Nasal (NPA) Airways:

- b. Particularly useful and often underused in pediatrics.
- c. Oral airways should only be used in unconscious patients .
- d. Oral airways can be helpful in lifting the large pediatric tongue that is obstructing an airway.
- e. **OPA Sizing:** Measure the airway along the side of the patient's face from mouth to the angle of the mandible. EMTprep provides a useful video at <a href="https://youtu.be/D00lunbXP6g">https://youtu.be/D00lunbXP6g</a>.
- f. Nasopharyngeal airways can be used in **conscious** patients.
- g. NPA should be used cautiously in young infants because their large adenoids and tonsils can be injured during insertion, resulting in bleeding
- h. Insert NPA with bevel pointed away from septum to decrease risk of bleeding
- NPA Sizing: To choose the correct size, be sure the airway extends from the nostril to the tragus of the ear. Lubrication improves ease of passage. Nostril size should be used as a guide for width. EMTprep provides a useful video at https://youtu.be/oJgpWPiH-Q4.
- j. Indications: upper airway obstruction
- k. **Contraindications:** NPA in patients with suspected basilar fracture, CSF leak, coagulopathy; OPA: alert/awake patients.



# **Bag-Mask Ventilation:**

- I. Remains an essential skill for pediatric providers and can be used as a temporizing measure.
- m. E-C clamp is the most common technique used; **lift** the jaw into the mask or perform a chin lift; 2 hand technique is another option.
- n. Avoid compression of neck soft tissues, as well as submental soft tissues when holding the jaw.
- o. Start with approximately 5 cm  $H_2O$  of continuous positive airway pressure and titrate up as needed to maintain ventilation.
- p. Normal tidal volume: 6-8ml/kg + dead space; estimate 10 ml/kg to cause chest rise.
- q. If a 1 yr old 10 kg child requires 80 to 100 ml per breath, this is the equivalent of 6 tablespoons of air.
- r. Ventilations with Bag Valve Mask (BVM) breaths every 3-5 sec (12-20 breaths per minute).
- s. Passive exhalation should be greater than inspiratory time. "Squeeze-release-release" is a helpful pacing technique.
- t. Overventilation: The consequences of overventilation are particularly problematic in children. It can lead to gastric distention, emesis, difficulty ventilating because of elevation of the hemi-diaphragm.
- u. CPAP and BiPAP are also options in pediatric patients; nasal prongs are used in infants and neonates.

To prevent overventilation, only squeeze until chest rise is seen.



Remember that repositioning, suctioning, supplemental oxygen, and adjuncts (OPA,NPA) can go a long way in managing the pediatric airway. Try these first before moving on to intubation.

# **Invasive Interventions:**

# Emergent Endotracheal Intubation

a. Equipment: Similar standard equipment as with adult intubation (oxygen, suction, ETCO2 detector, etc) with the exception of a choice in blade type and tube type.



# Should a cuffed or uncuffed tube be used?

- b. Previous concern was expressed over the use of cuffed tubes in children under 8 years old, due to a risk of ischemic damage to tracheal tissue from compression between the cuff and the cricoid ring. Adding to this risk is the narrow diameter at the cricoid.
- c. This is now less of a risk because of the improved design of more modern ETTs, therefore use of cuffed tubes in younger ages is increasing. Microcuff tubes may be used for smaller pediatric patients as well.

### Sizing:

d. Laryngoscope Blade:

Age	Weight (kg)	Laryngoscope Blade Size
Premature/ Newborn	1 - 3	Miller 0
1 month to 2 years	3.5 - 12	Miller 1
3 - 6 years	15 - 20	Miller 2, MacIntosh 2 (by 5 vo)
6 - 12 years	20 - 35	Miller 2, MacIntosh 2 or 3
>12 years	>35	MacIntosh 3

# Endotracheal Tube (ETT):

e. Use a length based tape for endotracheal tube sizing (e.g., Broselow tape), but if not available, use the equations below:

Uncuffed tubes: [Age (in years)/4] + 4

Example: [4 years old/4] + 4 = 5 uncuffed Cuffed tubes: [Age (in

years)/4] + 3.5

Example: [4 years old/4] + 3.5 = 4.5 cuffed



Use of the equations has been shown to be more accurate than using the width of the patient's fifth finger.

- f. Depth of Insertion:
  - i. Neonates and Infants: The "1, 2,3, 4--7,8,9,10 rule" has been commonly used (cuffed tubes). For example, a 1 kg infant will have the tubed taped at



7 cm at the maxillary alveolar ridge (not lip), 2kg infant at 8 cm, etc.


- ii. Older Children: Multiply the internal diameter (in mm) x 3
- g. Cuffed Tube Inflation:
  - i. No more than 20 cm  $H_2O$  (mucosal blood flow to trachea is compromised at 30 cm  $H_2O$ )
  - ii. An acceptable air leak with a cuffed tube (deflated) is 15-25 cm  $H_2O$

-`@`-

Adult airway diameter is narrowest at the level of the vocal cords, while in children, <u>the narrowest diameter is at the cricoid ring</u>. Therefore, an ETT may fit through the vocal cords but be too large to pass through the cricoid ring.

# **Endotracheal Intubation Technique**

1. An infant's epiglottis is narrow, and short, angled into the airway lumen (see image below). The epiglottis descends to a lower cervical station as a child ages (C2-C3 at birth then C4-C5 by age 3).



2. Larynx position is higher in infancy.

**Tip:** Use a straight rather than a curved blade.

3. Large occiput can result in neck flexion and difficulty visualizing airway.

Tip: Apply "shoulder roll" if less than 2 years old.





Suboptimal airway positioning



Improved airway positioning

4. Simple extension of the head as opposed to the traditional "sniffing position" may improve alignment of oral, pharyngeal, and tracheal a 5. The recommendation to use a Miller blade in infants in young children is based on anatomical studies NOT comparative studies with the McIntosh blade.

**Tip:** Miller blade can be placed BEHIND the epiglottis to lift it up or by moving the tip of the blade just behind the epiglottis; if using a Macintosh, place the place the tip behind the epiglottis, in the vallecula.

6.Miller blade may help with tongue displacement and better control, but it is **most important** to use the blade you are most experienced using.

7.iv.If there is difficulty visualizing the glottis, external manipulation can improve the view using the "backwards-upward-rightward pressure" on the thyroid (BURP maneuver).

The difficult airway mnemonic, DOPES, is applicable in pediatrics also. DOPES stands for Displacement, Obstruction, Pneumothorax, Esophageal placement/Equipment malfunction, Stacking (breath stacking). Consider these five elements when a patient fails to respond appropriately to ventilation via an endotracheal tube.



# Commonly used Rapid Sequence Intubation (RSI) Medications:

RAPID S	EQUENCE INTUBATION	N (RSI) Medications: SE	EDATION
Medication	Dose	Side Effects	Contraindication
Etomidate	0.3mg/kg IV	Transient adrenal suppression	Septic Shock
Ketamine	1-2 mg/kg, 3- 7mg/kg IM	Controversy over effect in increased intracranial pressure	
Propofol	1-1.5 mg/kg IV	Hypotension	Avoid in infants
Midazolam	0.2-0.3mg/kg IV (max 10 mg)	May cause hemodynamic instability at doses needed for sedation	
Fentanyl	1-5mcg/kg	Give over 30 to 60 sec to avoid chest wall rigidity and respiratory depression	

RAPID	SEQUENCE INTUBATIO	N (RSI) Medications: P	Paralytic
Medication	Dose	Side Effects	Contraindication
Rocuronium	1mg/kg IV		
Succinylcholine	Infants and children ≤2 years old: 2 mg/kg IV >2 years old: 1.5 mg/kg (4 mg/kg IM)	Controversy over effect in increased intracranial pressure	Do not use with crush injury (extensive), rhabdomyolysis, Becker Muscular Dystrophy, Cerebral Palsy with paralysis, 48-72 hours after burn injury, multiple trauma, history of malignant hyperthermia, hyperkalemia



### Source: UptoDate, "Rapid Sequence Intubation in Emergency Settings"

#### Appendix D: Pocket Medication Reference

#### https://www.utahptn.org/wp-content/uploads/2022/08/Drug-Reference-with-Safety-version-2.2.pdf

#### Pediatric Emergency Room Pocket Drug Reference Version 2.2

Poison Control 1-800-222-1222

9	Common	Medications	
Medication	Route	Dose	Max
Acetaminophen	PO	15 mg/kg	650 mg
Fentanyl	IV	1 mcg/kg	50 mcg
	Nasal	2 mcg/kg	100 mcg
Ibuprofen	PO	10 mg/kg	600 mg
Ketamine	IV	1mg/kg	
-Alternative	IV	1.5 mg/kgx1 the	n 0.75mg/kg
Midazolam	IV	0.05 mg/kg	5 mg
-Min sedation	Nasal	0.4 mg/kg	10 mg
Morphine	IV	0.05-0.1mg/kg	4 mg
Ondansetron	IV	0.1mg/kg	4 mg
Propofol*	IV	1 mg/kg	40 mg
	*ma	y repeat up to 5 to	tal doses

Written medication order correct format: Medication-Dose (mg/kg)--Total Dose--Route--Frequency

Medication-Dose (mg/kg)--Total Dose--Route--Frequenc

Do not use these abbreviations: U, IU, QD, QOD, MS, MSO4, MGSO4

#### No leading decimal, use 0.1 mg, NOT .1 mg No trailing zero, use 1 mg, NOT 1.0 mg

	Naus	ea		
Medication	Route	Dose	Max	
Metoclopramide	IV	0.1-0.2 mg/kg	10 mg	
Ondansetron	IV/PO	0.1 mg/kg	4 mg	
Prochlorperazine ≥ 2 years old	IV	0.1-0.15 mg/kg	10 mg	
Promethazine NOT IN HAND IV!!!	IV/PO	0.25-1 mg/kg	25 mg	

	Pain		
Medication	Route	Dose	Max
Acetaminophen	PO/PR	15 mg/kg	650 mg
Diazepam-Spasms	IV	0.05 mg/kg	5 mg
Fentanyl	IV	1 mcg/kg	50 mcg
	IN	2 mcg/kg	100mcg
Hydrocodone/APAP	PO	0.1-0.2 mg/kg	10mg
Hydromorphone	IV	10-15 mcg/kg	500mcg
Ibuprofen	PO	10 mg/kg	600 mg
Ketorolac	IV	0.5-1 mg/kg	30 mg
Morphine	IV	0.05-0.1 mg/kg	4 mg
Oxycodone<6month	PO	0.025- 0.05 mg/kg	5 mg
>6month	PO	0.05- 0.15 mg/kg	10 mg

	S	edation		
Medication	Route	Dose	Max	
Midazolam	IV	0.05-0.1 mg/kg	3 mg	
	IN	0.4 mg/kg	10 mg	
Ketamine	IV	1 mg/kg	Sector A	
Alternative	IV	1.5 mg/kg x1 then 0.5 mg/kg		
Ondansetron	IV	0.1 mg/kg	4 mg	
Propofol	IV	1 mg/kg	40 mg	
	*m:	ay repeat up to 5 to	tal doses	

Pedia	atric Adva	anced Life Supp	port
Medication	Route	Dose	Max
Adenosine	IV	0.1 mg/kg	First-6 mg
-Second Dose	IV	0.2 mg/kg	Second-12mg
Amiodarone	IV	5 mg/kg	300 mg
Atropine	IV	0.02 mg/kg	Max 0.5 mg
Calcium GLUC	IV	100 mg/kg	2000 mg
Epinephrine	IV	0.01 mg/kg	1mg(or>50kg)
-0.1mg/mL		(0.1 mL/kg)	(10 mL)

Rap	id Sec	uence	Intubation	
Medication	Rou	te	Dose	Max
Atropine	IV	0	.02 mg/kg	Max 0.5 mg
Etomidate	- IV	( ) (	).3 mg/kg	20mg
Lidocaine (个ICP)	IV	(	1 mg/kg	100 mg
Rocuronium	IV	(	1 mg/kg	-
Succinylcholine	IV	(	2 mg/kg	150 mg
Vecuronium	IV	he i led	).1 mg/kg	-
	A	naphyla	xis	
Medication		Route	Dose	Max
Epinephrine 1mg/r	mL	IM	0.01 mg/kg	0.3 mg
Dexamethasone		PO	0.6 mg/kg	16 mg
Diphenhydramine		IV/PO	1 mg/kg	50 mg
Panitidino		iN	1 malka	EOma

PO 2 mg/kg	
PU 2 mg/kg	150mg
Famotidine IV/PO 0.5 mg/kg	20mg
Methylprednisolone IV 1 mg/kg	

Medication	Route	Dose	Max
Dextrose 10%	IV	5 mL/kg	250 mL
NACL 3%	IV	5 mL/kg	500 mL
Mannitol	IV	0.5-1 gm/kg	50 gm
Sodium Bicarb	IV	1 mEq/kg	50 mEq
	<5	g use 4.2%	

A DOLLAR STREET	Antibio	tics	-
Medication	Route	Dose	Max
Acyclovir AdjBW->	IV	10-15 mg/kg	11.00.000.000
HSV<90 days	IV	20 mg/kg	
	PO	20 mg/kg	800mg
AMOXicillin Dosage forms	PO	25-50 mg/kg ng caps, 400mg/5mL	1000 mg
AMOXacillin/Clav (Augmentin) Dosage Forms: 250mg	PO	20-45 mg/kg	2000 mg
AMPicillin	IV	50 mg/kg	2000 mg
Ampicillin/sulbact (Unasyn)	IV	50 mg/kg	2000 mg (amp)
Azithromycin (Zithromax)	IV/PO	10 mg/kg STD→ tabs, 200 mg/5mL	500 mg 1000mg
Cefazolin (Ancef)	IV	33-50 mg/kg	2000 mg
Cefdinir (Omnicef) Dosage Forms: 3	PO Ome cao 1	7-14 mg/kg 25 mg/5mL 250 mg/5	600 mg
Ceftazidime (Fortaz)	IV	50 mg/kg	2000 mg
Cefotaxime (Claforan)	IV	50-75mg/kg	2000 mg
Cefoxitin (Mefoxin)	IV	40 mg/kg	2000 mg
Ceftriaxone (Rocephin)	IV	50-100 mg/kg	2000 mg
Cephalexin (Keflex) Dosage Forms:	PO 250mg 50	12.5-25 mg/kg Omg caps, 250mg/Sm	1000 mg
Clindamycin (Cleocin)	IV/PO	13 mg/kg Toxic Shock->	600 mg 900 mg
Gentamicin	IV	5-7.5 mg/kg	IBW
Metronidazole (Flagyl)	IV	10 mg/kg	500 mg
Appendicitis	IV	30 mg/kg	1500 mg
Piperacillin/Tazo (Zosyn)	IV	75 mg/kg	3000 mg (pip)
Vancomycin	IV	20 mg/kg	2000 mg

Cardiovascular Drips			
Medication	Route	Starting Range	
Dopamine	IV	5-20 mcg/kg/min	
Epinephrine	IV	0.05-1 mcg/kg/min	
Milrinone	IV	0.25-0.75 mcg/kg/min	
Norepinephrine	IV	0.05-1 mcg/kg/min	
Alprostadil	IV	0.05-0.1 mcg/kg/min	

	Reversal	Agents	
Medication	Route	Dose	Max
Naloxone-Partial	IV	0.01 mg/kg	0.2 mg
Naloxone-Full	IV/IM	0.1 mg/kg	2 mg
Flumazenil	IV	0.01 mg/kg	0.2 mg

	Respira	atory	
Medication	Route	Dose	Max
Albuterol	Neb	2.5mg/3mL	10 mg
Ipratropium	Neb	0.5 mg	1 mg
Magnesium -Give over 20 min	IV	50 mg/kg	2000 mg
Albuterol -Continuous	Neb	<20 kg- 10 mg/hr ≥20 kg- 20 mg/hr	
Racemic Epi	Neb	0.5 mL	In 3 mL NS
Dexamethasone	PO	0.6mg/kg	16 mg

Seizures				
Medication	Route	Dose	Max	
Fosphenytoin	IV	20 mg/kg	1500 mg	
Levetiracetam	IV	20 mg/kg	2000 mg	
-Benzo refractory	IV	60 mg/kg	4500 mg	
Lorazepam	IV	0.1 mg/kg	4 mg	
Phenobarbital	IV	20 mg/kg	1000 mg	
Valproic Acid	IV	20-40 mg/kg		
Midazolam	IN	0.2 mg/kg	10mg	

1

This document presents an evidenced-based approach that is appropriate for most patients. It should be adapted to meet the needs of individual

		mbinations	1
Medication	Route	Dose	Max
Appendiciti			
Ceftriaxone	IV	75mg/kg	2000 mg
Metronidazole	IV	30 mg/kg	1500 mg
Asthma LVN	N.	TV=17ml	
Albuterol	Neb	10 mg	
Ipratropium	Neb	1 mg	
Croup			
Racemic Epi	Neb	0.5 mL	TV=3.5m
Dexamethasone	PO/IV/ IM	0.6 mg/kg	16 mg
Migraine			
Prochlorperazine	IV	0.15mg/kg	10 mg
Diphenhydramine	IV	1 mg/kg	50 mg
Ketorolac	IV	1 mg/kg	30 mg
Choosing Augment	tin Conc	1 at 1 at 1 at 1 at 1	
High Dose-90mg/	kg/day	AugmentinES	600mg/5m
All other dosi	ng	Augmentin	NON ES
All other dosi	ng	Augmentin	NON ES
All other dosi	ng	Augmentin	NON ES
All other dosi	ng	Augmentin	NON ES
All other dosi	ng	Augmentin	NON ES
All other dosi	ng	Augmentin	NON ES
All other dosi	ng	Augmentin	NON ES
All other dosi	ng	Augmentin	NON ES
All other dosi		Augmentin	NON ES
All other dosi		Augmentin	NON ES
All other dosi		Augmentin	NON ES
		Augmentin	NON ES
Zero I	Harm Safe		
Zero I ARCC-Ask, Requ	Harm Safe	ty Techniques	
Zero I ARCC-Ask, Requ	Harm Safe Juest, Conc andardize	ty Techniques ern, Chain of Cor d Handoff	mmand
Zero I ARCC-Ask, Req St SBAR-Situation, Baci	Harm Safe Jest, Conc andardize kground, A	ty Techniques ern, Chain of Coi d Handoff ssessment, Recom	mmand
Zero I ARCC-Ask, Req St SBAR-Situation, Baci	Harm Safe Jest, Conc andardize kground, A Stop, Thin	ty Techniques ern, Chain of Coi d Handoff ssessment, Recom	mmand
Zero 1 ARCC-Ask, Requ St SBAR-Situation, Bac STAR-	Harm Safe Juest, Conc andardize kground, A Stop, Thin Stop and	ty Techniques ern, Chain of Coi d Handoff ssessment, Recom	mmand



Concerning vital signs by age		IR	R	R	Systolic BP	Ţe	mp
0 days - <1 mo	< 80	> 205	< 30	> 60	< 60	< 36	> 38
≥ 1 mo – < 3 mos	< 80	> 205	< 30	> 60	< 70	< 36	> 38
≥ 3 mos – < 1 yr	< 75	> 190	< 30	> 60	< 70	< 36	> 38.5
$\geq$ 1 yr - < 2 yrs	< 75	> 190	< 24	> 40	< 70 + (age x 2)	< 36	> 38.5
$\geq$ 2 yrs - < 4 yrs	< 75	> 190	< 24	> 40	< 70 + (age x 2)	< 36	> 38.5
$\geq$ 4 yrs – 6 yrs	< 60	> 140	< 22	> 34	< 70 + (age x 2)	< 36	> 38.5
$\geq$ 6 yrs - < 10 yrs	< 60	> 140	< 18	> 30	< 70 + (age x 2)	< 36	> 38.5
≥ 10 yrs - < 13 yrs	< 60	> 100	< 18	> 30	< 90	< 36	> 38.5
≥ 13 yrs - < 18 yrs	< 60	> 100	< 12	> 16	< 90	< 36	> 38.5

### Additional Resources

**ASPR TRACIE:** <u>Pediatric Surge Resources</u> page and technical report on using <u>high flow nasal cannulas</u> in pediatric patients.

FDA: Guidance on navigating a shortage of tracheostomy tubes (Nov. 1)



# Appendix E

# Initial oral empiric antibiotics for outpatient treatment of pediatric community-acquired pneumonia (UpToDate 11/18/2022)

Age group	Empiric regimen
to 6 months	
Bacterial (not <i>Chlamydia</i> <i>trachomatis</i> )	Infants <3 to 6 months of age with suspected bacterial pneumonia should be hospitalized
C. trachomatis	Refer to UpToDate topic on C. trachomatis infections in the newborn
months to 5 years	
Typical	Amoxicillin <sup>¶</sup> 90 mg/kg per day in 2 or 3 divided doses (MAX 4 g/day), <b>or</b>
bacterial*	Amoxicillin-clavulanate 90 mg/kg per day of the amoxicillin component in 2 or 3 divided doses (MAX 4 g/day amoxicillin component)
	For children with mild reactions to a penicillin and no features of an IgE-mediated reaction $^{\Delta}$ :
	<ul> <li>Amoxicillin 90 mg/kg per day in 2 or 3 divided doses (MAX 4 g/day), or</li> </ul>
	<ul> <li>Amoxicillin-clavulanate 90 mg/kg per day of the amoxicillin component in 2 or 3 divided doses (MAX 4 g/day amoxicillin component), or</li> </ul>
	<ul> <li>A third-generation cephalosporin, such as cefdinir 14 mg/kg per day in 2 divided doses (MAX 600 mg/day) in communities with a low rate of pneumococcal resistance to penicillin</li> </ul>
	For children with IgE-mediated or serious delayed reaction to a penicillin:
	<ul> <li>Levofloxacin<sup>6</sup> 16 to 20 mg/kg per day in 2 divided doses (MAX 750 mg/day), or</li> </ul>
	<ul> <li>Clindamycin 30 to 40 mg/kg per day in 3 or 4 divided doses (MAX 1.8 g/day), or</li> </ul>
	<ul> <li>Linezolid 30 mg/kg per day in 3 divided doses (MAX 1.8 g/day)</li> </ul>
	In communities with a high rate of pneumococcal resistance to penicillin:



	<ul> <li>Levofloxacin<sup>6</sup> 16 to 20 mg/kg per day in 2 divided doses (MAX 750 mg/day), or</li> </ul>				
	<ul> <li>Linezolid 30 mg/kg per day in 3 divided doses (MAX 1.8 g/day)</li> </ul>				
25 years					
Mycoplasma pneumoniae or	Azithromycin <sup>1</sup> 10 mg/kg on day 1 followed by 5 mg/kg daily for 4 more days (MAX 500 mg on day 1 and 250 mg thereafter), <b>or</b>				
Chlamydia pneumoniae	Clarithromycin 15 mg/kg per day in 2 divided doses (MAX 1 g/day), or				
	Erythromycin 40 to 50 mg/kg per day in 4 divided doses (MAX 2 g/day as base, 3.2 g/day as ethylsuccinate), <b>or</b>				
	Doxycycline 4 mg/kg per day in 2 divided doses (MAX 200 mg/day), or				
	Levofloxacin <sup>◊</sup> 8 to 10 mg/kg once daily for children 5 to 16 years (MAX 500 mg/day); 500 mg once daily for children ≥16 years, <b>or</b>				
	Moxifloxacin <sup>◊§</sup> 400 mg once daily (≥18 years)				
Typical	Amoxicillin <sup>1</sup> 90 mg/kg per day in 2 or 3 divided doses (MAX 4 g/day)				
bacterial*	For children with mild reactions to a penicillin and no features of an IgE-mediated reaction $^{\Delta}$ :				
	<ul> <li>Amoxicillin 90 mg/kg per day in 2 or 3 divided doses (MAX 4 g/day), or</li> </ul>				
	<ul> <li>A third-generation cephalosporin, such as cefdinir 14 mg/kg per day in 2 divided doses (MAX 600 mg/day)</li> </ul>				
	For children with IgE-mediated or serious delayed reaction to a penicillin:				
	<ul> <li>Levofloxacin<sup>◊</sup> 8 to 10 mg/kg once daily for children 5 to 16 years (MAX 750 mg/day); 750 mg once daily for children ≥16 years, or</li> </ul>				
	<ul> <li>Clindamycin 30 to 40 mg/kg per day in 3 or 4 divided doses (MAX 1.8 g/day), or</li> </ul>				
	<ul> <li>Linezolid 30 mg/kg per day in 3 divided doses (MAX 1.8 g/day) for children &lt;12 years; 20 mg/kg per day divided in 2 doses (MAX 1.2 g/day) for children ≥12 years</li> </ul>				
	In communities with a high rate of pneumococcal resistance to penicillin:				
	<ul> <li>Levofloxacin<sup>◊</sup> 8 to 10 mg/kg once daily for children 5 to 16 years (MAX 750 mg/day); 750 mg once daily for children ≥16 years, or</li> </ul>				



	<ul> <li>Linezolid 30 mg/kg per day divided in 3 doses (MAX 1.8 g/day) for children &lt;12 years; 20 mg/kg per day divided in 2 doses (MAX 1.2 g/day) for children ≥12 years</li> </ul>
Aspiration pneumonia	
Community- acquired	Amoxicillin-clavulanate 40 to 50 mg/kg per day in 2 or 3 divided doses (MAX 1.75 g/day amoxicillin component)
	For children with mild reactions to a penicillin and no features of an IgE-mediated reaction <sup><math>\Delta</math></sup> :
	<ul> <li>Amoxicillin-clavulanate 40 to 50 mg/kg per day in 2 or 3 divided doses (MAX 1.75 g/day amoxicillin component)</li> </ul>
	For children with IgE-mediated or serious delayed reaction to amoxicillin:
	<ul> <li>Clindamycin 30 to 40 mg/kg per day divided in 3 or 4 doses (MAX 1.8 g/day)</li> </ul>
	<ul> <li>Moxifloxacin<sup>◊</sup> 400 mg once daily (for ≥18 years)</li> </ul>

https://www.uptodate.com/contents/image/print?topicKey=PEDS%2F5987&view=machineLearning&search=c ommunity%20acquired%20pneumonia%20treatment%20children&sectionRank=1&usage\_type=default&image Key=PEDS%2F80561&rank=1~150&source=machineLearning&display\_rank=1



### Links, References, and Acknowledgements:

This document can be found and referenced at: https://wrap-em.org/

The content and evidence based resources have been consolidated in this document from multiple other pediatric respiratory protocols from numerous children's Hospitals. We would like to recognize with gratitude the sharing of these individual guidelines!

CHLA

Primary Utah

Seattle Children's

Stanford - LPCH

UC Davis

UCSF-Oakland and San Francisco

### <u>LINKS</u>

ASPR Tracie list of resources for Respiratory care with High Flow Oxygen for children:

https://files.asprtracie.hhs.gov/documents/aspr-tracie-ta---pediatrics-and-high-flow-nasal-cannulas.pdf

Stanford University - pediatric ICU mechanical ventilation education module: <u>http://www.learnpicu.com/respiratory/Mechanical-Ventilation</u>

CHOP <a href="https://www.chop.edu/clinical-pathway/bronchiolitis-inpatient-treatment-clinical-pathway">https://www.chop.edu/clinical-pathway/bronchiolitis-inpatient-treatment-clinical-pathway</a>

Heated High flow nasal Cannula ventilation "how to" video: https://youtu.be/Z9JDTHo9yUM

Open Pediatrics: Numerous videos, simulations, and training modules on pediatric respiratory care. Free registration on the site is required to access content. <u>https://www.openpediatrics.org/</u>

"10 common pediatric airway problems - and their solutions" :

https://www.anesthesiologynews.com/Review-Articles/Article/08-19/10-Common-Pediatric-Airway-Problems-And-Their-Solutions/55657?sub=B9BFD2B22AAB91C738BEFA44BD6987A27AB424466CD7E09740FF4A4786780



### Reference Literature:

- King MA, et al; PICU in the MICU: How Adult ICUs Can Support Pediatric Care in Public Health Emergencies. Chest. 2022 May;161(5):1297-1305. doi: 10.1016/j.chest.2021.12.648. Epub 2022 Jan 7. PMID: 35007553;
- 2. Shawn L, et al; Clinical Practice Guideline: The Diagnosis, Management, and Prevention of Bronchiolitis. *Pediatrics* November 2014; 134 (5): e1474–e1502. 10.1542/peds.2014-2742
- Kirolos A, et al; A Systematic Review of Clinical Practice Guidelines for the Diagnosis and Management of Bronchiolitis. J Infect Dis. 2020 Oct 7;222(Suppl 7):S672-S679. doi: 10.1093/infdis/jiz240. Erratum in: J Infect Dis. 2020 Mar 16;221(7):1204.
- 4. Kwon JW. **High-flow nasal cannula oxygen therapy in children: a clinical review**. Clin Exp Pediatr. 2020 Jan;63(1):3-7. doi: 10.3345/kjp.2019.00626. Epub 2019 Oct 28.
- 5. American Academy of Pediatrics, **Diagnosis and Management of Bronchiolitis**, Subcommittee on Diagnosis and Management of Bronchiolitis, Pediatrics. 2014; 134(2):415-420.
- 6. Dawson KP, Long A, Kennedy J, Mogridge N. **The chest radiograph in acute bronchiolitis**. J Paediatr Child Health. 1990 26(4):209-211.
- 7. Farley R, Spurling GK, Eriksson L, Del Mar CB. **Antibiotics for bronchiolitis in children under two years of age**. Cochrane Database Syst Rev. 2014;2014(10) doi:10.1002/14651858.CD005189.pub4
- Freeman JF, Deakyne S, Bajaj L. Emergency Department-initiated Home Oxygen for Bronchiolitis: A Prospective Study of Community Follow-up, Caregiver Satisfaction, and Outcomes. Acad Emerg Med. 2017;24(8):920-929.
- 9. Gadomski AM, Brower M. Bronchodilators for bronchiolitis. Cochrane Database Syst Rev. 2010;(12):CD001266.
- 10. Patel H, Platt R, Lozano JM, Wang EE. **Glucocorticoids for acute viral bronchiolitis in infants and young children**. Cochrane Database Syst Rev.2004;(3):CD004878.
- Principi T, Coates AL, Parkin PC, Stephens D, DaSilva Z, Schuh S. Effect of Oxygen Desaturations on Subsequent Medical Visits in Infants Discharged From the Emergency Department With Bronchiolitis. JAMA Pediatr. 2016;170(6):1-7.
- 12. Roback MG, Dreitlein DA. Chest radiograph in the evaluation of first time wheezing episodes: review of current clinical efficacy. Pediatr Emerg Care. 1998 Jun;14(3):181-4.
- 13. Sandweiss DR, Mundorff MB, et al. Decreasing Hospital Length of Stay for Bronchiolitis by Using an Observation Unit and Home Oxygen Therapy. JAMA Pediatr. 2013;167(5):422-428.
- 14. Schuh S, Freedman S, et al. Effect of Oximetry on Hospitalization in Bronchiolitis. J Am Med Assoc. 2014;312(7):712-718.
- 15. Von Woensel JB, van Aalderen WM, Kimpen JL. **Viral lower respiratory tract infection in infants and young children.** BMJ 200;327(7405):36–40.

Version 1b – David McCarthy 11/21/22